Company Encyclopedia
View More
name
Immuron Limited
IMC.AU
News
View More

Immuron Reports Strong FY2025 Results and Outlines FY2026 Plans

Immuron Limited reported strong FY2025 results, with a 49% increase in global sales revenue, driven by performance in Australia and North America. The company achieved FDA approval for IMM-529 IND and completed a successful Travelan® trial. Looking ahead, Immuron plans to initiate a Phase 2 trial for IMM-529 in FY2026. However, analysts rate IMRN stock as a Sell with a $1.50 price target, citing poor financial performance and a bearish technical trend. Immuron specializes in developing orally delivered targeted polyclonal antibodies for infectious diseases.

Tip Ranks·
US
IMRN
-1.27%
Tip Ranks·
US
IMRN
-1.27%

Immuron Limited Issues 8.5 Million Shares in Private Placement

Immuron Limited has issued 8,495,080 ordinary shares in a private placement, which will be quoted on the ASX under the code IMC, effective November 7, 2025. This brings the total number of quoted ordinary shares to 277,848,893. No further securities are expected to be issued in this transaction.

Reuters·
Reuters·

Immuron Announces New Securities Issue to Boost R&D Funding

Immuron Limited announced a proposed issue of 8,495,080 ordinary securities at AUD 0.07560 each to fund R&D and working capital. The shares will be sold to US investors via H.C. Wainwright & Co. This move aims to enhance financial resources for R&D initiatives. Currently, analysts rate IMRN stock as a Sell with a $1.50 price target, citing poor financial performance and a bearish trend. Immuron focuses on developing oral immunotherapeutics for gut-mediated diseases, with a market cap of $13.67M.

Tip Ranks·
US
IMRN
-1.27%
Tip Ranks·
US
IMRN
-1.27%

Immuron Limited Announces US$8.5 Million Share Placement to US Investors

Immuron Limited has announced a share placement of up to 8,495,080 ordinary shares to US investors through its US At-The-Market facility, managed by H.C. Wainwright & Co. The issuance will occur on July 11, 2025, with no changes to the company's dividend policy. The facility is characterized as low fee and no discount, and the company has confirmed compliance with Australian law regarding secondary sales.

Reuters·
Reuters·

FDA Approves IND Application for Immuron’s IMM-529 to Treat C. difficile Infection

Immuron Limited has received FDA approval for its IND application for IMM-529, enabling a Phase 2 clinical trial for treating Clostridioides difficile infection (CDI). The drug, which uses antibodies from hyperimmune bovine colostrum, aims to prevent and treat CDI, including recurrent cases. The trial is set to begin in the first half of 2026. This announcement was made on November 05, 2025, and is for informational purposes only, not to be considered as financial or legal advice.

Reuters·
Reuters·